课题基金 / 基金详情

ALENDRONATE TO IMPROVE BONE MINERAL DENSITY IN BOYS W/DUCHENNE MUSCULAR DYSTROPH

ALENDRONATE TO IMPROVE BONE MINERAL DENSITY IN BOYS W/DUCHENNE MUSCULAR DYSTROPH
阿仑膦酸钠可改善患有杜氏肌营养不良症的男孩的骨矿物质密度
批准号:
7605080
负责人:
SUSAN APKON
金额:
$0.37万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-03-01 至 2008-02-29

项目摘要

项目成果

SUSAN APKON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Fractures are a significant source of morbidity in boys with Duchenne muscular dystrophy (DMD), as they not only cause discomfort, but can also precipitate early loss of ambulation (1;2). This is likely related to progressive weakness and subsequent immobility, which has been associated with osteoporosis. Glucocorticoids have been used in the treatment of DMD to slow the progression of weakness and loss of function and have been shown to induce osteoporosis (3). The combination of immobility and glucocorticoid treatment, may, thus predispose these children to fractures resulting from minimal trauma. The use of Dual Energy X-ray Absorptiometry (DXA) has allowed the determination and monitoring of bone mineral density (BMD) in children. DXA scans have shown significantly decreased BMD in boys with Duchenne muscular dystrophy (4;5). Thus, treatment to improve BMD could potentially decrease the risk of fractures and its associated morbidity. The use of bisphosphonate medications in children with osteoporosis improves BMD without significant side effects (6-8). We propose a randomized, double-blinded, placebo controlled study using weekly oral alendronate, a bisphosphonate to improve bone mineral density in boys with Duchenne muscular dystrophy. The control group will receive daily Vitamin D and calcium and a weekly placebo pill. The experimental group will receive these supplements as well as weekly oral alendronate. Bone mineral density will be evaluated at baseline, 6 months, and a year. We hypothesize that the boys receiving alendronate, a bisphosphonate, and oral calcium and vitamin D supplements will have a greater improvement in bone mineral density than boys receiving oral supplements alone.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ALENDRONATE TO IMPROVE BONE MINERAL DEN IN BOYS W/DUCHENNE MUSC DYSTROPHY
  • 批准号:
    7374353
  • 项目类别:
  • 资助金额:
    $1.03万
  • 财政年份:
    2006
  • 负责人:
    SUSAN APKON
  • 依托单位:
ALENDRONATE TO IMPROVE BONE MINERAL DENSITY IN BOYS W/DUCHENNE MUSCULAR DYSTROPH
  • 批准号:
    7202417
  • 项目类别:
  • 资助金额:
    $0.59万
  • 财政年份:
    2005
  • 负责人:
    SUSAN APKON
  • 依托单位:
Alendronate to Improve Bone Mineral Density in Boys
  • 批准号:
    7041046
  • 项目类别:
  • 资助金额:
    $0.04万
  • 财政年份:
    2004
  • 负责人:
    SUSAN APKON
  • 依托单位:
DEXA to Measure Bone Den. in Children with Spina Bifida
  • 批准号:
    7041013
  • 项目类别:
  • 资助金额:
    $0.19万
  • 财政年份:
    2004
  • 负责人:
    SUSAN APKON
  • 依托单位:
海外基金